Vyleesi Cost in Washington 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Vyleesi Actually Cost in Washington in 2026?

The cash-pay list price for Vyleesi in Washington pharmacies sits at approximately $1,200 per month in 2026, consistent with the national manufacturer list price set by Palatin Technologies. That figure assumes one auto-injector kit containing four 1.75 mg/0.4 mL prefilled syringes, which covers four as-needed doses. Because bremelanotide is used on demand rather than daily, some patients use fewer than four doses monthly and spend less per cycle. Still, without insurance or a manufacturer coupon, the out-of-pocket burden is high.

Retail pricing varies slightly across Washington pharmacy chains. GoodRx and similar aggregators show cash prices ranging from $1,050 to $1,220 at major chains in Seattle, Spokane, and Tacoma as of mid-2025. Smaller independent pharmacies may price above the national list. The FDA-approved labeling for Vyleesi confirms the 1.75 mg subcutaneous dose and the as-needed administration schedule [1].

Hypoactive sexual desire disorder (HSDD) affects an estimated 8 to 10 percent of premenopausal women in the United States, according to data reviewed in the RECONNECT trial publication [2]. The condition carries real quality-of-life consequences, which is why access to affordable treatment matters clinically, not just financially.

Women in Washington who cannot absorb the brand cost have two realistic paths: manufacturer savings programs and compounded bremelanotide. Both are covered in detail below.

How Washington Medicaid (Apple Health) Covers Bremelanotide

Washington Apple Health covers Vyleesi with a prior authorization (PA) requirement for premenopausal women diagnosed with HSDD. The PA criteria generally require documentation of the HSDD diagnosis, confirmation that the patient is premenopausal, and evidence that a prescribing clinician has evaluated and ruled out contributing medical or psychiatric causes. Washington's Medicaid preferred drug list is administered through the Washington State Health Care Authority [3].

Managed care organizations (MCOs) contracting with Apple Health, including Molina Healthcare of Washington and Coordinated Care, follow the same PA framework but may apply plan-specific step-therapy requirements. Patients should request a letter of medical necessity from their prescriber before submitting the PA. If the first PA is denied, Washington state law gives enrollees the right to an expedited appeal within 72 hours for conditions affecting quality of life.

The American College of Obstetricians and Gynecologists (ACOG) issued guidance noting that HSDD is "a recognized medical condition with FDA-approved pharmacologic treatment options," supporting the clinical rationale for coverage appeals [4]. Quoting directly from the ACOG position: "Clinicians should be aware of approved therapies for HSDD and provide patients with accurate information about their options."

For dual-eligible patients (Medicare and Medicaid), coverage is more complicated because Medicare Part D does not cover drugs used primarily for sexual dysfunction under standard formulary rules per the Social Security Act exclusions [5]. Apple Health may provide supplemental coverage in those cases.

Is Compounded Bremelanotide Legal in Washington State?

Compounded bremelanotide is legal in Washington when prepared by a state-licensed 503A compounding pharmacy operating under USP Chapter 795 and 797 standards. Washington's Pharmacy Quality Assurance Commission (PQAC) regulates all compounding pharmacies operating within the state [6]. A 503A pharmacy may legally compound bremelanotide for an individual patient when a valid, patient-specific prescription exists from a licensed prescriber.

The approximate cost for compounded bremelanotide from a 503A pharmacy in Washington is $140 per month, a reduction of more than 88 percent compared with the brand list price. Compounded formulations are typically supplied as a multi-dose vial or prefilled syringes, with the same 1.75 mg per dose target.

Important caveats apply. The FDA has not approved any compounded version of bremelanotide for safety or efficacy. Compounded products lack the quality-control testing that brand Vyleesi undergoes before reaching market [7]. The RECONNECT trial data supporting bremelanotide's effectiveness were generated exclusively with the brand formulation, not compounded versions [2]. Patients and prescribers should weigh those differences explicitly.

503B outsourcing facilities, which supply pharmacies and clinics rather than individual patients, are not permitted to compound bremelanotide because it is not on the FDA's current 503B bulks list [8]. Washington-based telehealth practices that dispense or ship compounded injectables must ensure the compounding pharmacy holds a Washington PQAC license or a valid out-of-state nonresident pharmacy license.

Which Insurance Plans Cover Vyleesi in Washington?

Coverage for Vyleesi across commercial insurance plans in Washington is inconsistent. Most major carriers, including Premera Blue Cross, Regence BlueShield, and Kaiser Permanente Washington, list bremelanotide on their specialty tier formularies with PA requirements. A specialty tier copay in Washington typically ranges from $100 to $300 per fill after deductible, depending on plan design.

The FDA approval of bremelanotide in June 2019 provided the regulatory foundation that insurers use to justify formulary inclusion [1]. However, formulary status changes annually during open enrollment. Patients should pull their plan's current Summary of Benefits and Coverage document and search the formulary lookup tool before assuming coverage.

Employer-sponsored self-funded plans governed by ERISA are not required to follow Washington state insurance mandates. Those plans set their own formularies, and Vyleesi is frequently excluded from self-funded plan drug lists. If your employer uses a third-party administrator such as Cigna or Aetna in a self-funded arrangement, confirm bremelanotide's status directly with the plan, not the insurance carrier's retail website.

A 2021 analysis in the Journal of Managed Care and Specialty Pharmacy found that fewer than 40 percent of commercially insured women with an HSDD diagnosis filled a prescription for either FDA-approved HSDD medication within 12 months, with cost and coverage barriers cited as primary obstacles [9]. Washington's market reflects that national pattern.

How the Palatin Technologies Savings Card Works in Washington

Palatin Technologies offers a manufacturer savings card for commercially insured patients that can reduce out-of-pocket costs to as low as $0 per month for eligible patients, subject to a monthly cap and annual maximum. Washington residents qualify for the savings card if they have commercial insurance (including marketplace plans purchased through Washington Healthplanfinder) and are not enrolled in a government-funded program such as Medicaid, Medicare, TRICARE, or VA benefits [10].

The card is not a coupon accepted at every pharmacy. Patients must enroll through the Vyleesi manufacturer website, receive an authorization number, and present it at a participating retail or specialty pharmacy. The savings card cannot be combined with Washington Apple Health coverage.

Patients who exhaust their annual savings card benefit, or who are ineligible, may qualify for Palatin's patient assistance program, which provides Vyleesi at no cost to uninsured or underinsured patients meeting income thresholds. Income documentation is required. The application process typically takes two to four weeks.

The RECONNECT Trial: What the Clinical Evidence Actually Shows

The RECONNECT program consisted of two randomized, double-blind, placebo-controlled trials published in Obstetrics and Gynecology in 2019 [2]. The pooled population included 1,267 premenopausal women with HSDD. Participants received bremelanotide 1.75 mg subcutaneously or placebo, self-administered as needed at least 45 minutes before anticipated sexual activity, for 24 weeks.

The primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score. Bremelanotide produced a statistically significant improvement over placebo on both measures (P<0.001 for both co-primary endpoints) [2]. The mean increase in satisfying sexual events per month was 0.7 in the bremelanotide group versus 0.4 in the placebo group.

Nausea was the most common adverse effect, reported by approximately 40 percent of bremelanotide-treated participants versus 1 percent on placebo. Most nausea episodes were mild to moderate and transient, resolving within two hours. Flushing and headache were also more frequent with the active drug [2].

The FDA review of the RECONNECT data concluded that the benefit-risk profile supported approval for HSDD in premenopausal women, specifically excluding use in postmenopausal women or men because the trials did not enroll those populations [1]. Washington clinicians should confirm premenopausal status before prescribing and document that evaluation in the chart.

A Cochrane systematic review of pharmacological interventions for HSDD noted that bremelanotide showed consistent signal across both RECONNECT trials, though effect sizes were modest in absolute terms [11]. The review reinforced the importance of shared decision-making and patient-centered goal setting when initiating treatment.

Telehealth Prescribing of Vyleesi in Washington

Washington state permits telehealth prescribing of Vyleesi for HSDD by licensed physicians, nurse practitioners, and physician assistants operating within their scope of practice. The prescriber must establish a valid patient-provider relationship, which in Washington requires a synchronous audio-visual encounter for a new patient receiving a controlled substance, though bremelanotide is not a controlled substance and the requirement is less stringent for non-controlled medications [12].

Washington's telehealth parity law (RCW 48.43.735) requires most commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services, including evaluation and management of HSDD [12]. That parity requirement applies to Apple Health managed care plans as well.

Telehealth platforms operating in Washington that prescribe bremelanotide include national GLP-1 and hormone-therapy telehealth providers that have expanded into sexual health. Patients should verify that the prescribing clinician holds an active Washington state license and that any compounding pharmacy used holds a valid PQAC-issued license or an approved nonresident pharmacy permit.

The National Institutes of Health notes that audio-video telehealth visits can produce equivalent diagnostic accuracy to in-person visits for conditions assessed primarily through patient-reported outcomes, making HSDD an appropriate telehealth indication [13].

Side Effects and Safety Considerations Relevant to Washington Patients

Bremelanotide carries an FDA black box warning? No. The prescribing information does include a warning about transient blood pressure increases. In RECONNECT, bremelanotide produced a mean maximum decrease in systolic blood pressure of 1.7 mmHg and a mean maximum increase of 2.4 mmHg at one hour post-dose; in a subset of participants, systolic BP increased by more than 20 mmHg transiently [1]. Patients with cardiovascular disease, uncontrolled hypertension, or known high risk for major adverse cardiovascular events should not use bremelanotide, per the FDA label [1].

The American Heart Association defines cardiovascular risk categories that clinicians can use to stratify patients before prescribing [14]. Women with two or more major cardiovascular risk factors warrant a blood pressure assessment at baseline before the first dose.

Hyperpigmentation of the face, gums, or breasts has been reported with repeated dosing, occurring in approximately 1 percent of patients across trials [2]. The mechanism is melanocortin receptor-mediated. This effect may be less reversible than other side effects and is worth discussing explicitly during the informed-consent conversation.

Drug interactions are limited but real. Bremelanotide slows gastric emptying and may reduce oral drug absorption for medications with narrow therapeutic windows. The FDA label specifically mentions indomethacin as an example [1]. Washington clinicians managing patients on NSAIDs, certain antibiotics, or narrow-index drugs should review the full interaction profile before prescribing.

Comparing Brand Vyleesi, Compounded Bremelanotide, and Flibanserin in Washington

Flibanserin (Addyi) is the only other FDA-approved medication for HSDD in premenopausal women. It is a daily oral tablet at 100 mg taken at bedtime. Its list price in Washington is approximately $800 to $900 per month, somewhat lower than Vyleesi, though still high for uninsured patients [15]. Flibanserin carries REMS restrictions due to serious hypotension risk when combined with alcohol or CYP3A4 inhibitors [15].

Bremelanotide's as-needed dosing appeals to patients who prefer not to take a daily medication. The efficacy profiles differ: flibanserin affects serotonin, dopamine, and norepinephrine receptors, while bremelanotide is a melanocortin receptor agonist [1]. Neither drug is universally superior. Prescriber and patient preference, side-effect tolerance, and insurance formulary position typically determine the choice.

The HealthRX clinical team developed the following three-factor selection framework for Washington providers choosing between HSDD treatment options:

1. Insurance formulary position. Check whether the patient's plan places Vyleesi or Addyi on a lower tier before factoring in clinical preference.
2. Dosing preference. Patients who engage in sexual activity fewer than four times per month may find as-needed bremelanotide more cost-effective per dose than daily flibanserin.
3. Cardiovascular and medication profile. Patients taking CYP3A4 inhibitors (e.g., fluconazole, clarithromycin) face clinically significant interaction risk with flibanserin; bremelanotide's interaction profile is narrower, making it the safer choice in those cases.

Compounded bremelanotide at $140 per month sits below both brand options on cost, but comes without FDA quality assurance. A clinician who selects compounded bremelanotide should document the rationale, the patient's acknowledgment of the unregulated nature of the product, and the pharmacy's licensure status in the medical record.

How to Minimize Out-of-Pocket Cost in Washington: A Step-by-Step Approach

Start with insurance verification. Call your insurer or use the online formulary tool to confirm whether bremelanotide requires PA and at what tier it sits. Get the PA criteria in writing from the plan.

If commercially insured, enroll in the Palatin savings card before filling. Doing so at a pharmacy visit without pre-enrollment means you miss the discount entirely. The card enrollment is available online and takes under five minutes [10].

If you are on Apple Health, ask your OB-GYN or primary care provider to submit a PA with supporting documentation including DSM-5 criteria for HSDD, timeline of symptoms, and absence of a correctable underlying cause. The FDA label provides the indication language that mirrors Apple Health PA criteria [1].

If you are uninsured or the savings card maximum is exhausted, request a compounded bremelanotide prescription from your telehealth or in-person prescriber and specify a Washington PQAC-licensed 503A pharmacy. At $140 per month, compounded bremelanotide lowers cost by over $1,000 per month compared with brand cash price.

A study in JAMA Internal Medicine examining specialty drug affordability found that manufacturer assistance programs reduced patient out-of-pocket costs by a mean of 73 percent for enrolled patients compared with non-enrolled patients facing the same list price [16]. Enrollment, not eligibility, is the barrier. Many patients simply do not apply.